Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
Structure Therapeutics Inc. - American Depositary Shares (GPCR)
Company Research
Source: GlobeNewswire
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company’s once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day. To access the live webcast, please visit the Investor Relations page of the company’s website at https://ir.structuretx.com/events-presentations/events. To access the call by phone, participants should visit this link to receive dial-in details. The webcast will be made available for replay on the company's website beginning approximately two hours after the live event. The replay of the webc
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics (GPCR) valuation check after Phase 1 obesity candidate ACCG-2671 enters first-in-human trial [Yahoo! Finance]Yahoo! Finance
- Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]Yahoo! Finance
- Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of ObesityGlobeNewswire
- Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GPCR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
GPCR
Sec Filings
- 12/10/25 - Form 8-K
- 12/10/25 - Form 424B5
- 12/10/25 - Form 4
- GPCR's page on the SEC website